Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland.
Donegan K, Doerholt K, Judd A, Lyall H, Menson E, Butler K, Tookey P, Riordan A, Shingadia D, Tudor-Williams G, Gibb DM, Walker AS; Collaborative HIV Paediatric Study (CHIPS). Donegan K, et al. Among authors: gibb dm. Pediatr Infect Dis J. 2013 Jan;32(1):45-50. doi: 10.1097/INF.0b013e31827842c9. Pediatr Infect Dis J. 2013. PMID: 23076384
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004.
Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, Riordon A, Lyall H, Tookey P, Butler K, Sabin CA, Gibb D, Pillay D; Collaborative HIV Paediatric Study; UK Collaborative Group on HIV Drug Resistance. Chakraborty R, et al. Pediatr Infect Dis J. 2008 May;27(5):457-9. doi: 10.1097/INF.0b013e3181646d6f. Pediatr Infect Dis J. 2008. PMID: 18382385
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, Lallemant M, Gibb DM, Burger DM; Paediatric European Network for Treatment of AIDS II Study Group. Cressey TR, et al. Among authors: gibb dm. Clin Infect Dis. 2008 May 15;46(10):1601-8. doi: 10.1086/587657. Clin Infect Dis. 2008. PMID: 18419497 Free PMC article. Clinical Trial.
Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland.
Kekitiinwa A, Lee KJ, Walker AS, Maganda A, Doerholt K, Kitaka SB, Asiimwe A, Judd A, Musoke P, Gibb DM; Collaborative HIV Paediatric Study (CHIPS) Steering Committe; Mulago Cohort Team. Kekitiinwa A, et al. Among authors: gibb dm. J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):384-92. doi: 10.1097/QAI.0b013e31818cdef5. J Acquir Immune Defic Syndr. 2008. PMID: 18931630
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D; Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Ndembi N, et al. Among authors: gibb dm. J Infect Dis. 2010 Jan 1;201(1):106-13. doi: 10.1086/648590. J Infect Dis. 2010. PMID: 19938977 Clinical Trial.
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
DART Trial Team; Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, Reid A, Grosskurth H, Darbyshire JH, Ssali F, Bray D, Katabira E, Babiker AG, Gilks CF, Grosskurth H, Munderi P, Kabuye G, Nsibambi D, Kasirye R, Zalwango E, Nakazibwe M, Kikaire B, Nassuna G, Massa R, Fadhiru K, Namyalo M, Zalwango A, Generous L, Khauka P, Rutikarayo N, Nakahima W, Mugisha A, Todd J, Levin J, Muyingo S, Ruberantwari A, Kaleebu P, Yirrell D, Ndembi N, Lyagoba F, Hughes P, Aber M, Lara AM, Foster S, Amurwon J, Wakholi BN, Whitworth J, Wangati K, Amuron B, Kajungu D, Nakiyingi J, Omony W, Fadhiru K, Nsibambi D, Khauka P, Mugyenyi P, Kityo C, Ssali F, Tumukunde D, Otim T, Kabanda J, Musana H, Akao J, Kyomugisha H, Byamukama A, Sabiiti J, Komugyena J, Wavamunno P, Mukiibi S, Drasiku A, Byaruhanga R, Labeja O, Katundu P, Tugume S, Awio P, Namazzi A, Bakeinyaga GT, Katabira H, Abaine D, Tukamushaba J, Anywar W, Ojiambo W, Angweng E, Murungi S, Haguma W, Atwiine S, Kigozi J, Namale L, Mukose A, Mulindwa G, Atwiine D, Muhwezi A, Nimwesiga E, Barungi G, Takubwa J, Murungi S, Mwebesa D, Kagina G, Mulindwa M, Ahimbisibwe F, Mwesigwa P, Akuma S, Zawedde C, Nyiraguhirwa D, Tumusiime C, Bagaya … See abstract for full author list ➔ DART Trial Team, et al. Among authors: gibb dm. Lancet. 2010 Jan 9;375(9709):123-31. doi: 10.1016/S0140-6736(09)62067-5. Epub 2009 Dec 8. Lancet. 2010. PMID: 20004464 Free PMC article. Clinical Trial.
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
Kityo C, Walker AS, Dickinson L, Lutwama F, Kayiwa J, Ssali F, Nalumenya R, Tumukunde D, Munderi P, Reid A, Gilks CF, Gibb DM, Khoo S; DART Trial Team. Kityo C, et al. Among authors: gibb dm. Antimicrob Agents Chemother. 2010 Jul;54(7):2965-73. doi: 10.1128/AAC.01198-09. Epub 2010 Apr 26. Antimicrob Agents Chemother. 2010. PMID: 20421406 Free PMC article. Clinical Trial.
376 results